Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround

Core Viewpoint - AEON Biopharma, Inc. has experienced significant selling pressure, resulting in a 64.2% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Stock Performance - AEON's stock is currently in oversold territory, indicated by an RSI reading of 24.09, suggesting that the heavy selling may be exhausting itself [4] - The stock has lost 64.2% in value over the last month, highlighting the extent of the selling pressure [1] Group 2: Earnings Estimates - There has been a strong consensus among sell-side analysts to raise AEON's earnings estimates, with a 22.9% increase in the consensus EPS estimate over the last 30 days [4] - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [4] Group 3: Analyst Ratings - AEON currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5] - This ranking serves as a strong indicator of the stock's potential for a turnaround in the near term [5]